| Literature DB >> 31632094 |
V A Varney1,2, A Nicholas2, A Warner2, N Sumar2.
Abstract
BACKGROUND: The renin-angiotensin system (RAS) protects the circulation against sudden falls in systemic blood pressure via generation of angiotensin II (AII). Previously, we demonstrated that patients with anaphylaxis involving airway angioedema and cardiovascular collapse (AACVS) had significantly increased "I" gene polymorphisms of the angiotensin-converting-enzymes (ACE). This is associated with lower serum ACE and AII levels and was not seen in anaphylaxis without collapse nor atopics and healthy controls.Entities:
Keywords: ACE genotype; IgE-mediated anaphylaxis; angioedema; angiotensinogen M235T; chymase CMA1-1903; endothelial nitric oxide
Year: 2019 PMID: 31632094 PMCID: PMC6790349 DOI: 10.2147/JAA.S213016
Source DB: PubMed Journal: J Asthma Allergy ISSN: 1178-6965
Figure 1Terr’s classification of anaphylaxis grades 1–4.
Note: Data from Terr.1
Figure 2Tri-allelic ensemble of the 27 genes combinations of AGT, CMA1 and ACE for healthy controls (HC) and anaphylaxis.
Note: *Genes in the analysis.
Ensemble Of 6 Common Gene Combinations
| Tri-Allelic Ensemble | HC (No. Of Cases) | Anaphylaxis (No. Of Cases) | AACVS (No. Of Cases) |
|---|---|---|---|
| II or ID | 11 | 29 | 26 |
| DD | 29 | 7 | 6 |
| DD | 8 | 6 | 4 |
| ID | 10 | 16 | 8 |
| Total no. (% of total in group) | 47 (40%) | 58 (48%) | 44 (46%) |
| Chi square HC versus anaphylaxis* andAACVS* | – | Anaphylaxis | AACVS |
Note: *Chi-square analysis with significance p<0.025.
Abbreviation: AACVS, airway angioedema ± cardiovascular collapse.
Demographics Of Subjects
| Subject Groups | Mean Age ±SD (Age Range) | Serum ACE±SD Levels U/L | Ethnic Groups | Allergen Sensitivity And (Number Of Subjects) |
|---|---|---|---|---|
| Healthy controls N=119 | 53±11.1 (25–71) | 48.9±25 | 95% Caucasian | None |
| Atopic controls N=52 | 47±13.7 (18–77) | 47.9±25 | 87% Caucasian Asian 10% Chinese 3% | Fish (3) |
| Anaphylaxis group (venom, food & drug) N=122 | 45±14.0 (16–71) | 33.8±21 | 93% Caucasian | Wasp (35) Bee (9) Nut/fruit (36) |
| Cause of anaphylaxis and | Venom n=44 | Foods/drugs/latex | ||
| Symptom onset | ||||
| Total no. of anaphylaxis | 94 stings | 170 reactions | ||
| AACVS reaction for venom/foods | 84% (n=37 subjects) | 74% (n=58 subjects) | ||
| Terr’s classification of anaphylaxis | Venom | Food/drug/latex | Total of subjects in each grade | |
| Grade 1 | 2 | 8 | 10 | |
| Grade 2 | 16 | 39 | 55 | |
| Grade 3 | 24 | 28 | 52 | |
| Grade 4 | 2 | 3 | 5 | |
Abbreviation: AACVS, angioedema and cardiovascular collapse.
Angiotensinogen Genes For The Groups And Terr’s Classification
| AGT Genotype (% Of Cases) | MM | MT | TT | Healthy Controls* | Atopics* | Anaphylaxis* | CRA* |
|---|---|---|---|---|---|---|---|
| Healthy controls | 42 (35%) | 63 (53%) | 14 (12%) | ||||
| Atopic controls | 20 (38%) | 24 (46%) | 8 (16%) | P=0.671 | |||
| Anaphylaxis | 56 (46%) | 43 (35%) | 23 (19%) | P=0.019 | P=0.399 | ||
| CRA+ anaphylaxis only | 11 (41%) | 11 (41%) | 5 (18%) | P=0.449 | P=0.883 | P=0.89 | |
| AACVS+ anaphylaxis | 45 (48%) | 32 (33%) | 18 (19%) | P=0.017 | P=0.330 | P=0.98 | P=0.778 |
| Significance | The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example healthy control versus anaphylaxis p =0.019.*Chi square with 2df with significance at < 0.005.
| ||||||
| Grade 1 | 0 | 9 | 1 | ||||
| Grade 2 | 26 | 16 | 13 | ||||
| Grade 3 | 27 | 16 | 9 | P=0.718 | |||
| Grade 4 | 3 | 2 | 0 | P=0.220 | P=0.468 | P=0.593 | |
| Statistical significance | *Chi square with 2df with #p-value significant <0.008.The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example grade 1 versus grade 4 Terr p =0.220 | ||||||
Chymase CMA1-1903 Genotype Frequency For The Groups
| Chymase Genotype (% Of Cases) | AA | AG | GG | Healthy* Controls | Atopics* | Cutaneous* & RS |
|---|---|---|---|---|---|---|
| Healthy controls (HC)n=119 | 23 (19%) | 65 (55%) | 31 (26%) | |||
| Atopic controlsn=52 | 7 (14%) | 32 (61%) | 13 (25%) | P=0.597 | ||
| Anaphylaxis | 19 (16%) | 66 (54%) | 37 (30%) | P=0.648 | P=0.661 | |
| CRA | 1 (3%) | 15 (56%) | 11 (41%) | P=0.072 | P=0.1991 | |
| AACVS | 18 (19%) | 51 (54%) | 26 (27%) | P=0.976 | P=0.596 | P=0.111 |
Notes: *Chi-square with 2df with significance at p<0.006. The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example healthy controls versus CRA p =0.072.
Abbreviations: CRA, cutaneous & respiratory anaphylaxis; AACVS, airway angioedema ± cardiovascular collapse.
Chymase CMA-1 A1903G And AGT M235T Bi-Allelic Pairing For The Groups
| Shared Genotype (% Of Cases) | MM/AA | MM/AG | MM/GG | MT/AA | MT/AG | MT/GG | TT/AA | TT/AG | TT/GG | HC* | Atopics* | Anaphylaxis* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthy controls (HC)n=119 | 7 (6%) | 20 (17%) | 16 (13.5%) | 10 (8%) | 37 (31%) | 16 (13.5%) | 6 (5%) | 6 (5%) | 1 (1%) | |||
| Atopic controlsn=52 | 2 (4%) | 12 (23%) | 6 (11%) | 2 (4%) | 16 (31%) | 5 (9.5%) | 2 (4%) | 5 (9.5%) | 2 (4%) | P=0.67 | ||
| Anaphylaxisn=122 | 9 (7%) | 38 (31%) | 11 (9%) | 7 (6%) | 21 (17%) | 15 (13%) | 3 (2%) | 7 (6%) | 11 (9%) | P=0.47 | ||
| CRA | 0 | 6 (22%) | 5 (19%) | 1 (4%) | 6 (22%) | 3 (11%) | 0 | 2 (7%) | 4 (15%) | P=0.063 | ||
| AACVS | 9 (10%) | 32 (34%) | 6 (6%) | 6 (6%) | 15 (16%) | 12 (13%) | 3 (3%) | 5 (5%) | 7 (7%) | P=0.99 |
Notes: The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example HC versus anaphylaxis p =0.005. *Chi square with 2df with significance at p< 0.008.
Abbreviations: CRA, cutaneous & respiratory anaphylaxis; AACVS, airway angioedema ± cardiovascular collapse.
AGT M235T And ACE I/D Gene Bi-Allelic Pairing For The Groups
| Shared Genotype | MM/II | MM/ID | MM/DD | MT/II | MT/ID | MT/DD | TT/II | TT/ID | TT/DD | HC* | Atopic* | Anaphylaxis* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthy controls (HC)n=119 | 7 (5%) | 20 (18%) | 16 (14%) | 12 (10%) | 19 (16%) | 32 (27%) | 4 (3%) | 5 (4%) | 4 (3%) | |||
| Atopic controlsn=52 | 3 (6%) | 12 (23%) | 5 (10%) | 3 (6%) | 9 (17%) | 12 (23%) | 2 (4%) | 6 (11%) | 0 | P=0.6 | ||
| Anaphylaxisn=122 | 18 (15%) | 29 (24%) | 9 (7%) | 7 (6%) | 26 (21%) | 10 (8%) | 8 (7%) | 10 (8%) | 5 (4%) | P=0.159 | ||
| CRA | 3 (11%) | 7 (26%) | 2 (7.5%) | 0 | 7 (26%) | 3 (11%) | 0 | 3 (11%) | 2 (7%) | P=0.089 | P=0.133 | P=0.83 |
| AACVS | 15 (16%) | 22 (24%) | 7 (7%) | 7 (7%) | 19 (20%) | 7 (7%) | 8 (9%) | 7 (7%) | 3 (3%) | P=0.416 | P=0.999 |
Notes: The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example HC versus anaphylaxis p =0.0013. *Chi-square with 2df with significance at p< 0.005.
Abbreviations: CRA, cutaneous & respiratory anaphylaxis; AACVS, airway angioedema ± cardiovascular collapse.
Bi-Allelic Pairing Of Chymase CMA-1 A1903G And ACE I/D Gene Combinations For The Different Groups
| Shared Genotype (% Of Cases) | AA/II | AA/ID | AA/DD | AG/II | AG/ID | AG/DD | GG/II | GG/ID | GG/DD | HC* | Atopic* | Anaphylaxis* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthy controls (HC)n=119 | 4 (3%) | 12 (10%) | 7 (6%) | 12 (10%) | 21 (18%) | 30 (25%) | 6 (5%) | 13 (11%) | 14 (12%) | |||
| Atopic controlsn=52 | 0 | 4 (8%) | 3 (6%) | 8 (15%) | 16 (31%) | 8 (15%) | 0 | 7 (14%) | 6 (11%) | P=0.03 | ||
| Anaphylaxis | 8 (6.5%) | 8 (6.5%) | 3 (2%) | 15 (13%) | 40 (33%) | 11 (9%) | 10 (8%) | 17 (14%) | 10 (8%) | P=0.14 | ||
| CRA | 0 | 0 | 1 (3%) | 0 | 12 (44%) | 3 (12%) | 2 (7%) | 6 (22%) | 3 (12%) | P=0.022 | P=0.26 | |
| AACVS | 8 (8%) | 8 (8%) | 2 (2.5%) | 15 (16%) | 28 (30%) | 8 (8%) | 8 (8%) | 11 (12%) | 7 (7.5%) | P=0.013 | P=0.99 |
Notes: The p values for the groups and subgroups are represented as a chequer board with significant values in bold for example HC versus anaphylaxis p =0.007. *Chi-square with 2df with significance at p< 0.007.
Abbreviations: CRA, cutaneous & respiratory anaphylaxis; AACVS, airway angioedema ± cardiovascular collapse.
Figure 3Diagram of the renin-angiotensin-aldosterone system.